Cargando…

Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin

BACKGROUND: COVID-19 has been associated with a high prevalence of myocardial injury and increased cardiovascular morbidity. Copeptin, a marker of vasopressin release, has been previously established as a risk marker in both infectious and cardiovascular disease. METHODS: This prospective, observati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufmann, Christoph C., Ahmed, Amro, Kassem, Mona, Freynhofer, Matthias K., Jäger, Bernhard, Aicher, Gabriele, Equiluz-Bruck, Susanne, Spiel, Alexander O., Vafai-Tabrizi, Florian, Gschwantler, Michael, Fasching, Peter, Wojta, Johann, Giannitsis, Evangelos, Huber, Kurt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592075/
https://www.ncbi.nlm.nih.gov/pubmed/34782921
http://dx.doi.org/10.1007/s00392-021-01970-4
_version_ 1784599387172765696
author Kaufmann, Christoph C.
Ahmed, Amro
Kassem, Mona
Freynhofer, Matthias K.
Jäger, Bernhard
Aicher, Gabriele
Equiluz-Bruck, Susanne
Spiel, Alexander O.
Vafai-Tabrizi, Florian
Gschwantler, Michael
Fasching, Peter
Wojta, Johann
Giannitsis, Evangelos
Huber, Kurt
author_facet Kaufmann, Christoph C.
Ahmed, Amro
Kassem, Mona
Freynhofer, Matthias K.
Jäger, Bernhard
Aicher, Gabriele
Equiluz-Bruck, Susanne
Spiel, Alexander O.
Vafai-Tabrizi, Florian
Gschwantler, Michael
Fasching, Peter
Wojta, Johann
Giannitsis, Evangelos
Huber, Kurt
author_sort Kaufmann, Christoph C.
collection PubMed
description BACKGROUND: COVID-19 has been associated with a high prevalence of myocardial injury and increased cardiovascular morbidity. Copeptin, a marker of vasopressin release, has been previously established as a risk marker in both infectious and cardiovascular disease. METHODS: This prospective, observational study of patients with laboratory-confirmed COVID-19 infection was conducted from June 6th to November 26th, 2020 in a tertiary care hospital. Copeptin and high-sensitive cardiac troponin I (hs-cTnI) levels on admission were collected and tested for their association with the primary composite endpoint of ICU admission or 28-day mortality. RESULTS: A total of 213 eligible patients with COVID-19 were included of whom 55 (25.8%) reached the primary endpoint. Median levels of copeptin and hs-cTnI at admission were significantly higher in patients with an adverse outcome (Copeptin 29.6 pmol/L, [IQR, 16.2–77.8] vs 17.2 pmol/L [IQR, 7.4–41.0] and hs-cTnI 22.8 ng/L [IQR, 11.5–97.5] vs 10.2 ng/L [5.5–23.1], P < 0.001 respectively). ROC analysis demonstrated an optimal cut-off of 19.3 pmol/L for copeptin and 16.8 ng/L for hs-cTnI and an increase of either biomarker was significantly associated with the primary endpoint. The combination of raised hs-cTnI and copeptin yielded a superior prognostic value to individual measurement of biomarkers and was a strong prognostic marker upon multivariable logistic regression analysis (OR 4.274 [95% CI, 1.995–9.154], P < 0.001). Addition of copeptin and hs-cTnI to established risk models improved C-statistics and net reclassification indices. CONCLUSION: The combination of raised copeptin and hs-cTnI upon admission is an independent predictor of ICU admission or 28-day mortality in hospitalized patients with COVID-19. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-021-01970-4.
format Online
Article
Text
id pubmed-8592075
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-85920752021-11-15 Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin Kaufmann, Christoph C. Ahmed, Amro Kassem, Mona Freynhofer, Matthias K. Jäger, Bernhard Aicher, Gabriele Equiluz-Bruck, Susanne Spiel, Alexander O. Vafai-Tabrizi, Florian Gschwantler, Michael Fasching, Peter Wojta, Johann Giannitsis, Evangelos Huber, Kurt Clin Res Cardiol Original Paper BACKGROUND: COVID-19 has been associated with a high prevalence of myocardial injury and increased cardiovascular morbidity. Copeptin, a marker of vasopressin release, has been previously established as a risk marker in both infectious and cardiovascular disease. METHODS: This prospective, observational study of patients with laboratory-confirmed COVID-19 infection was conducted from June 6th to November 26th, 2020 in a tertiary care hospital. Copeptin and high-sensitive cardiac troponin I (hs-cTnI) levels on admission were collected and tested for their association with the primary composite endpoint of ICU admission or 28-day mortality. RESULTS: A total of 213 eligible patients with COVID-19 were included of whom 55 (25.8%) reached the primary endpoint. Median levels of copeptin and hs-cTnI at admission were significantly higher in patients with an adverse outcome (Copeptin 29.6 pmol/L, [IQR, 16.2–77.8] vs 17.2 pmol/L [IQR, 7.4–41.0] and hs-cTnI 22.8 ng/L [IQR, 11.5–97.5] vs 10.2 ng/L [5.5–23.1], P < 0.001 respectively). ROC analysis demonstrated an optimal cut-off of 19.3 pmol/L for copeptin and 16.8 ng/L for hs-cTnI and an increase of either biomarker was significantly associated with the primary endpoint. The combination of raised hs-cTnI and copeptin yielded a superior prognostic value to individual measurement of biomarkers and was a strong prognostic marker upon multivariable logistic regression analysis (OR 4.274 [95% CI, 1.995–9.154], P < 0.001). Addition of copeptin and hs-cTnI to established risk models improved C-statistics and net reclassification indices. CONCLUSION: The combination of raised copeptin and hs-cTnI upon admission is an independent predictor of ICU admission or 28-day mortality in hospitalized patients with COVID-19. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-021-01970-4. Springer Berlin Heidelberg 2021-11-15 2022 /pmc/articles/PMC8592075/ /pubmed/34782921 http://dx.doi.org/10.1007/s00392-021-01970-4 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Paper
Kaufmann, Christoph C.
Ahmed, Amro
Kassem, Mona
Freynhofer, Matthias K.
Jäger, Bernhard
Aicher, Gabriele
Equiluz-Bruck, Susanne
Spiel, Alexander O.
Vafai-Tabrizi, Florian
Gschwantler, Michael
Fasching, Peter
Wojta, Johann
Giannitsis, Evangelos
Huber, Kurt
Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin
title Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin
title_full Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin
title_fullStr Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin
title_full_unstemmed Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin
title_short Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin
title_sort improvement of outcome prediction of hospitalized patients with covid-19 by a dual marker strategy using high-sensitive cardiac troponin i and copeptin
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592075/
https://www.ncbi.nlm.nih.gov/pubmed/34782921
http://dx.doi.org/10.1007/s00392-021-01970-4
work_keys_str_mv AT kaufmannchristophc improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin
AT ahmedamro improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin
AT kassemmona improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin
AT freynhofermatthiask improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin
AT jagerbernhard improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin
AT aichergabriele improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin
AT equiluzbrucksusanne improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin
AT spielalexandero improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin
AT vafaitabriziflorian improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin
AT gschwantlermichael improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin
AT faschingpeter improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin
AT wojtajohann improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin
AT giannitsisevangelos improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin
AT huberkurt improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin